Cargando…

Suppress for Success: A JAK Inhibitor for Adjunct Therapy of Tuberculosis

Detalles Bibliográficos
Autor principal:	Dorhoi, Anca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563134/ https://www.ncbi.nlm.nih.gov/pubmed/26425676 http://dx.doi.org/10.1016/j.ebiom.2015.08.010

Ejemplares similares

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis
por: Ahidjo, Bintou Ahmadou, et al.
Publicado: (2016)

Refractory granuloma faciale successfully treated with adjunct topical JAK inhibitor
por: Chen, Ailynna, et al.
Publicado: (2023)

A Comment on JAK Inhibitors for Treatment of Alopecia Areata
por: Trüeb, Ralph Michel, et al.
Publicado: (2018)

A new player in psoriatic arthritis: a JAK inhibitor
por: Sakkas, Lazaros I.
Publicado: (2017)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
por: Blume-Peytavi, Ulrike, et al.
Publicado: (2015)

ROCKing the JAKs
por: Peelman, Frank, et al.
Publicado: (2013)

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology
por: Jessica Chang, Ting Yi, et al.
Publicado: (2020)

The Emerging Role of Myeloid-Derived Suppressor Cells in Tuberculosis
por: Magcwebeba, Tandeka, et al.
Publicado: (2019)

Corrigendum: The Emerging Role of Myeloid-Derived Suppressor Cells in Tuberculosis
por: Magcwebeba, Tandeka, et al.
Publicado: (2019)

Arginine Adjunctive Therapy in Active Tuberculosis
por: Farazi, Aliasghar, et al.
Publicado: (2015)

Animal models for COVID-19 and tuberculosis
por: Corleis, Björn, et al.
Publicado: (2023)

Cognitive Stimulation Therapy as an Adjunctive Treatment for Mild to Moderate Dementia
por: Kumar, S. Sandeep, et al.
Publicado: (2023)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Neutrophils in Tuberculosis: Cell Biology, Cellular Networking and Multitasking in Host Defense
por: Borkute, Rachana R., et al.
Publicado: (2021)

Adjunctive corticosteroid therapy in patients with pulmonary tuberculosis
por: Lemos, Carolina Xavier, et al.
Publicado: (2022)

Commentary: Platelet-rich plasma is a useful adjunct but with caveats
por: Shanmugam, P Mahesh
Publicado: (2020)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

The interplay between inhibition of JAK2 and HSP90
por: Fridman, Jordan S., et al.
Publicado: (2012)

Composition and Clinical Significance of Exosomes in Tuberculosis: A Systematic Literature Review
por: Biadglegne, Fantahun, et al.
Publicado: (2021)

More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
por: Langley, Paul C
Publicado: (2020)

Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis
por: Maiga, Mamoudou, et al.
Publicado: (2015)

Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model
por: Subbian, Selvakumar, et al.
Publicado: (2016)

Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
por: Namour, Florence
Publicado: (2015)

Commentary: Can cryotherapy be used as an adjunct in select cases of recalcitrant endophthalmitis?
por: Das, Tarprasad
Publicado: (2019)

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy
por: Koppikar, Priya, et al.
Publicado: (2012)

Circulating miRNAs as new activators of the JAK-STAT3 pathway
por: Lam, David, et al.
Publicado: (2013)

Mass Events Trigger Malta's Second Peak After Initial Successful Pandemic Suppression
por: Cuschieri, Sarah, et al.
Publicado: (2020)

JAK2-STAT3 signaling: A novel function and a novel mechanism
por: Hofmann, Hans-Dieter, et al.
Publicado: (2012)

Commentary: Adjunctive agents in peribulbar anesthesia: Role of dexmedetomidine in vitreo-retinal surgeries
por: Bhandari, Sahil
Publicado: (2019)

Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor
por: Scheinberg, Morton, et al.
Publicado: (2021)

Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report
por: Ren, Mingyang, et al.
Publicado: (2023)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Two commentaries on ‘Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children’
por: Coovadia, Hoosen, et al.
Publicado: (2009)

Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
por: Malemud, Charles J.
Publicado: (2010)

JAK inhibitors suppress t(8;21) fusion protein-induced leukemia
por: Lo, Miao-Chia, et al.
Publicado: (2013)

Mycobacterium tuberculosis-Associated Necrotizing Pneumonia With Adjunctive Corticosteroid Therapy
por: Nguyen, Ho Lam, et al.
Publicado: (2019)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Human Monocytic Suppressive Cells Promote Replication of Mycobacterium tuberculosis and Alter Stability of in vitro Generated Granulomas
por: Agrawal, Neha, et al.
Publicado: (2018)

Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis
por: Leukes, Vinzeigh N., et al.
Publicado: (2021)

Successful glucose lowering therapy triumphs in heart failure
por: Rossing, Peter
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s08t3nt4ejmsofo9cj516j05t4